Thanks to the Republican tax legislation, pharmaceutical stocks are set to continue their heady northward trajectory in 2018.
Thanks to the Republican tax legislation, pharmaceutical stocks are set to continue their heady northward trajectory in 2018. This newly minted tax reform, after all, should spur a flurry of mergers and acquisitions (M&A) activity by permitting companies to repatriate their overseas profits at far more friendly tax rates moving forward.
